Quantitation of the P2Y1 Receptor with a High Affinity Radiolabeled Antagonist
- 1 November 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 62 (5) , 1249-1257
- https://doi.org/10.1124/mol.62.5.1249
Abstract
2-Chloro-N6-methyl-(N )-methanocarba-2′-deoxyadenosine-3′,5′- bisphosphate (MRS2279) was developed previously as a selective high-affinity, non-nucleotide P2Y1 receptor (P2Y1-R) antagonist (J Med Chem43:829–842, 2002; Br J Pharmacol135:2004–2010, 2002). We have taken advantage of theN6-methyl substitution in the adenine base to incorporate [3H]methylamine into the synthesis of [3H]MRS2279 to high (89 Ci/mmol) specific radioactivity and have used this molecule as a radioligand for the P2Y1-R. [3H]MRS2279 bound to membranes from Sf9 insect cells expressing recombinant human P2Y1-R but not to membranes from wild-type Sf9 cells or Sf9 cells expressing high levels of recombinant P2Y2 or P2Y12 receptors. Equilibrium binding of [3H]MRS2279 to P2Y1-R expressed in Sf9 membranes was with a high affinity (Kd= 8 nM) essentially identical to the apparent affinity of MRS2279 determined previously in studies of P2Y1-R–promoted inositol phosphate accumulation or platelet aggregation. A kinetically derivedKd calculated from independent determinations of the rate constants of association (7.15 × 107 M−1min−1) and dissociation (0.72 min−1) of [3H]MRS2279 also was in good agreement with the Kdderived from equilibrium binding studies. Competition binding assays with [3H]MRS2279 and P2Y1-R expressing Sf9 cell membranes revealed Ki values for the P2Y1-R antagonists MRS2279 (Ki = 13 nM),N6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2179; Ki = 84 nM), adenosine-3′, 5′-bisphosphate (Ki=900 nM), and pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid (Ki = 6 μM) that were in good agreement with antagonist activities of these molecules previously determined at the P2Y1-R in intact tissues. Moreover, [3H]MRS2279 also bound with high affinity (Kd = 4–8 nM) to Chinese hamster ovary (CHO) or 1321N1 human astrocytoma cells stably expressing the human P2Y1-R, but specific binding was not observed in wild-type CHO or 1321N1 cells. [3H]MRS2279 bound with high affinity (Kd = 16 nM) to a binding site on out-dated human platelets (5–35 receptors/platelet) and rat brain membranes (210 fmol/mg protein) that fit the expected drug selectivity of a P2Y1-R. Taken together, these results indicate that [3H]MRS2279 is the first broadly applicable antagonist radioligand for a P2Y receptor.Keywords
This publication has 35 references indexed in Scilit:
- Activity of adenosine diphosphates and triphosphates on a P2YT‐type receptor in brain capillary endothelial cellsBritish Journal of Pharmacology, 2001
- Acyclic Analogues of Deoxyadenosine 3‘,5‘-Bisphosphates as P2Y1 Receptor AntagonistsJournal of Medicinal Chemistry, 2000
- Deoxyadenosine Bisphosphate Derivatives as Potent Antagonists at P2Y1 ReceptorsJournal of Medicinal Chemistry, 1998
- Distribution of [35S]dATPαS binding sites in the adult rat neuraxisNeuropharmacology, 1997
- An examination of deoxyadenosine 5′(α‐thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptorBritish Journal of Pharmacology, 1997
- Molecular Cloning of a Novel P2 Purinoceptor from Human Erythroleukemia CellsJournal of Biological Chemistry, 1996
- Identification of 6H1 as a P2YPurinoceptor: P2Y5Biochemical and Biophysical Research Communications, 1996
- Characterisation of a recombinant P2Y purinoceptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Characterization of a P2Y Purinoceptor in the BrainBasic & Clinical Pharmacology & Toxicology, 1995
- P2-Purinergic Receptors: Subtype-Associated Signaling Responses and StructureAnnual Review of Pharmacology and Toxicology, 1995